Only in Titles

           Search results for: Monoclonal Anti Breast Cancer Resistance Protein produced in mouse    

paperclip

#   // Save this To Up


1807 related Products with:



Related Pathways

  •  
  • No related Items
paperclip

#25862760   // Save this To Up

An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.

Chemotherapies are limited by a narrow therapeutic index resulting in suboptimal exposure of the tumor to the drug and acquired tumor resistance. One approach to overcome this is through antibody-drug conjugates (ADC) that facilitate greater potency via target-specific delivery of highly potent cytotoxic agents.

2321 related Products with: An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.

Rabbit Anti-TNIP2 ABIN2 T Rabbit Anti-WT-1 Wilms Tu Rabbit Anti-WT-1 Wilms Tu Rabbit Anti-WT-1 Wilms Tu Embryonal tumor test tiss Rabbit Anti-IAA (Indole-3 Rabbit Anti-CLPTM1L CRR9 Rabbit Anti-WT-1 Wilms Tu Rabbit Anti-TNIP2 ABIN2 T Rabbit Anti-WT-1 Wilms Tu Rabbit Anti-WT-1 Wilms Tu Rabbit Anti-Integrin alph

Related Pathways

paperclip

#23033967   // Save this To Up

Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

One-third of breast cancers display amplifications of the ERBB2 gene encoding the HER2 kinase receptor. Trastuzumab, a humanized antibody directed against an epitope on subdomain IV of the extracellular domain of HER2 is used for therapy of HER2-overexpressing mammary tumors. However, many tumors are either natively resistant or acquire resistance against Trastuzumab. Antibodies directed to different epitopes on the extracellular domain of HER2 are promising candidates for replacement or combinatorial therapy. For example, Pertuzumab that binds to subdomain II of HER2 extracellular domain and inhibits receptor dimerization is under clinical trial. Alternative antibodies directed to novel HER2 epitopes may serve as additional tools for breast cancer therapy. Our aim was to generate novel anti-HER2 monoclonal antibodies inhibiting the growth of breast cancer cells, either alone or in combination with tumor necrosis factor-α (TNF-α).

2467 related Products with: Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.

Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse Rat monoclonal anti mouse FDA normal and tumor orga Rat monoclonal anti mouse

Related Pathways

paperclip

#22407832   // Save this To Up

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

The PI3K/Akt/mTOR pathway is an attractive target in HER2-positive breast cancer that is refractory to anti-HER2 therapy. The hypothesis is that the suppression of this pathway results in sensitization to anti-HER2 agents. However, this combinatorial strategy has not been comprehensively tested in models of trastuzumab and lapatinib resistance.

2296 related Products with: Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer and matched Breast cancer tissue arra ER Immunohistochemistry c Breast cancer test tissue Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra Breast cancer test tissue Breast cancer tissue arra

Related Pathways

paperclip

#21915634   // Save this To Up

Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Breast cancer stem cells (BrCSC) are resistant to common therapeutic modalities including chemotherapy, radiation, and hormonal agents. They are thought to contribute to treatment resistance, relapse, and metastases. This study examines the effect of a monoclonal anti-DR5 antibody (TRA-8) and chemotherapy (adriamycin, taxol) on BrCSC populations from basal-like breast cancer cell lines. Doubly enriched BrCSC (CD44(+), CD24(-), ALDH(+)) cells were exposed to TRA-8 and control reagents and examined for cytotoxicity, caspase activation, tumorsphere formation and tumorigenicity. Doubly enriched BrCSC populations expressed cell surface DR5 and were sensitive to TRA-8 mediated cytotoxicity with induction of caspase 8 and 3 activation. TRA-8 at sub-nanomolar concentrations inhibited 2LMP and SUM159 BrCSC tumorsphere formation and was more than 50-fold more inhibitory than TRAIL or anti-DR4 at equimolar concentrations. Chemotherapy treatment of 2LMP and SUM159 cell lines resulted in a relative increase of BrCSC, whereas TRA-8 produced a decrease in the percentage of BrCSC. TRA-8 exposure to 2LMP and SUM159 BrCSC preparations produced significant inhibition of tumorigenicity. DR5 maybe a therapeutic target on the surface of basal-like BrCSC which is amenable to agonistic monoclonal anti-DR5 therapy.

1340 related Products with: Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity.

Breast cancer tissue arra Monoclonal Anti-Breast Ca Breast cancer test tissue Breast cancer tissue arra Anti Breast Cancer Resist Breast cancer tissue arra Monoclonal Anti-Breast Ca Breast cancer test tissue Oral squamous cell cancer Breast cancer tissue arra Breast cancer tissue arra Breast cancer tissue arra

Related Pathways

paperclip

#11426640   // Save this To Up

The EGF receptor family as targets for cancer therapy.

Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been associated with a more aggressive clinical behavior. Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype. For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments. In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed. These MAbs have shown promising preclinical activity and 'chimeric' and 'humanized' MAbs have been produced in order to obviate the problem of host immune reactions. Clinical activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy. In addition to antibodies, compounds that directly inhibit receptor tyrosine kinases have shown preclinical activity and early clinical activity has been reported. A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.

2534 related Products with: The EGF receptor family as targets for cancer therapy.

Annexin V EGFP Apoptosis MarkerGene™ LysoLive™ Primary antibody IL-1RAc Endothelial Tube Formatio Dog Receptor-binding canc G protein-coupled recepto Cancer miRNA Profiling Pl Rabbit Anti-GAGE7 Cancer Annexin V EGFP Apoptosis Annexin V EGFP Reagent100 Formate Assay Kit Annexin V EGFP Reagent200

Related Pathways